Drugs & Targets Sarclisa in combination with carfilzomib, dexamethasone receives FDA approval for relapsed or refractory multiple myeloma April 02, 2021Vol.47 No.13
Drugs & Targets Futibatinib receives Breakthrough Designation from FDA for advanced cholangiocarcinoma April 02, 2021Vol.47 No.13
Drugs & Targets FDA issues Complete Response Letter on Keytruda in TNBC indication April 02, 2021Vol.47 No.13
Drugs & Targets Huyabio International and BMS to collaborate on melanoma clinical April 02, 2021Vol.47 No.13
Drugs & Targets European Commission approves Cabometyx + Opdivo for first-line advanced renal cell carcinoma April 02, 2021Vol.47 No.13
Drugs & Targets Copiktra receives Positive CHMP Opinion for relapsed and refractory CLL and refractory FL April 02, 2021Vol.47 No.13
Drugs & Targets Keytruda receives FDA approval for esophageal or GEJ carcinoma March 26, 2021Vol.47 No.12
Drugs & Targets Evotec, Takeda collaborate on strategic RNA targeting drug discovery and development March 26, 2021Vol.47 No.12
